First-in-human trial of an ingestible vitals-monitoring pill
Name
1-s2.0-S2666998623001849-main.pdf
Description
Published version
Size
4.44 MB
Format
Adobe PDF
Checksum (MD5)
191f07f47fd226b58dc49d1c59f424d4
Author(s)
Traverso, Giovanni
Finomore, Victor
Mahoney, James
Kupec, Justin
Stansbury, Robert
Bacher, Daniel
Pless, Benjamin
Schuetz, Shannon
Hayward, Alison
Langer, Robert
Date Issued
November 2023
Journal
Device
Publisher
Elsevier
Citation
Traverso, Giovanni, Finomore, Victor, Mahoney, James, Kupec, Justin, Stansbury, Robert et al. 2023. "First-in-human trial of an ingestible vitals-monitoring pill." Device, 1 (5).
Version
Final published version
Abstract
Ingestible electronics can transform how patients are diagnosed and treated across many conditions. We developed an ingestible vitals-monitoring pill (VM pill) capable of monitoring vital signs including respiratory rate and heart rate. VM pill performance was evaluated in a swine model of opiate overdose and in a human trial of patients in a sleep laboratory. Sleep studies involve admission to a facility, placement of multiple skin sensors, and overnight observation. We hypothesized that the VM pill could diagnose clinically significant changes in respiratory status, such as apnea, unobtrusively. The VM pill was evaluated in 10 human subjects with no adverse events. The data streams captured by the VM pill achieved high concordance with standard sleep study metrics. Ingestible vital sign monitors can transform the diagnosis of sleep-related respiratory disorders and can capture life-threatening events such as apnea or opioid overdose.
MIT Department
Massachusetts Institute of Technology. Department of Mechanical Engineering
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Division of Comparative Medicine
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.device.2023.100125
